Authors

• Hongqian Guo (ORCID: https://orcid.org/0000-0001-7243-667X)
• Zhongquan Sun
• Haishan Kadeerbai
• Yanxia Shi (ORCID: https://orcid.org/0000-0002-5414-8049)
• Sue Lee
• Seema Rao Gorla (ORCID: https://orcid.org/0009-0006-5256-2189)
• Xinan Sheng
• Xiaoping Zhang (ORCID: https://orcid.org/0000-0003-0995-4989)
• Yue Li (ORCID: https://orcid.org/0000-0002-5490-748X)
• Jun Zhang (ORCID: https://orcid.org/0000-0001-7886-6187)
• Jun Guo (ORCID: https://orcid.org/0000-0003-1759-0986)
• Siming Li (ORCID: https://orcid.org/0000-0001-7077-0404)
• Haiying Dong (ORCID: https://orcid.org/0000-0002-3909-3246)
• Eric H. Kim (ORCID: https://orcid.org/0000-0002-0284-8342)
• Yu Xie (ORCID: https://orcid.org/0009-0002-7487-8601)
• Chenming Xu (ORCID: https://orcid.org/0000-0002-8911-3452)

Institutions

• Central South University (CN)
• Sun Yat-sen University (CN)
• Pfizer (United States) (US)
• Peking University (CN)
• Fudan University (CN)
• Astellas Pharma (China) (CN)
• Peking University Cancer Hospital (CN)
• Huadong Hospital (CN)
• Zhongda Hospital Southeast University (CN)
• Nanjing Drum Tower Hospital (CN)
• Hunan Cancer Hospital (CN)
• Zhejiang Provincial People's Hospital (CN)
• Sun Yat-sen University Cancer Center (CN)
• Astellas Pharma (United States) (US)

Publication Details

Journal

Cancer Medicine

Published

2024-11-01

DOI

https://doi.org/10.1002/cam4.70368

Citations

7

Primary Topic

Bladder and Urothelial Cancer Treatments

Type

article

Field-Weighted Citation Impact

4.01

Funders

• Pfizer
• Seagen
• Astellas Pharma
• Astellas Foundation for Research on Metabolic Disorders